| 货号 | 9444-DG-100 |
| 别名 | DEN-4; Dengue Virus 4 NS1; Dengue virus Serotype 4; Dengue virus Type 4; DENV4; DENV4-NS1 | 全称 | Dengue Virus 4 Dominica/814669/1981 Polyprotein |
| 来源 | Human embryonic kidney cell, HEK293-derived Asp775-Ala1126, with a C-terminal 6-His tag |
| 产品组分 |
| 供应商 | R&D Systems |
| Entrez Gene IDs | 5075729 (Viral) |
| 内毒素水平 | <0.10 EU per 1 μg of the protein by the LAL method. |
| 生物活性 | Bioassay data are not available. |
| 溶解方法 | Reconstitute at 500 μg/mL in PBS. |
| 背景 | Denguevirus type 1 non-structural protein 1 (DENV4 NS1) is an approximately 50 kDa viral glycoprotein(1). Dengue viruses are mosquito-borne flaviviruses that exist in nature asfour distinct serotypes (DENV1-4) (2). Dengue virus NS1 can be found associated with cell membranes, within cellsand at the cell surface, or as secreted extracellular species. The secreted form of NS1 is known to be hexameric (1). Withincells, NS1 plays a significant role in virus replication and has been shown toco-localize with dsRNA and other components of viral replication complexes inviral-induced vesicle packets (1,3). Cell surface-associated and secreted NS1are profoundly immunogenic, and both the protein itself and the antibodies itelicits have been shown to contribute to either protection or pathogenesis and innate immune evasion (1, 3). Mature DENV4 NS1contains 352 amino acids (aa) and consists of 2 conserved N-glycosylation sitesand 12 invariant cysteine residues that form six intramolecular disulfide bonds (3). Mature DENV4 NS1 shares 69%, 73%,and 74% aa sequence identity with DENV1, DENV2, and DENV3 NS1, respectively. |
| Accession # | P09866 N-terminal Se |
| 运输条件 | Blue Ice |
| 预期分子量 | 40 kDa |
| SDS-PAGE | 44-53 kDa, reducing conditions |
| 存放说明 | -20℃ |
| 纯度 | >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining. |
| 参考文献 |
|
R&D Systems proteins are almost always sold with a bioassay to indicate activity. However, we recognize that sometimes proteins might be novel, and their bioactivity may not be well understood. In addition, some researchers may wish to use polypeptides to make antibodies. To facilitate the advancement of new science, we now offer our Innovator Series of proteins. |
